DE60137037D1 - Piperazindion-verbindungen - Google Patents
Piperazindion-verbindungenInfo
- Publication number
- DE60137037D1 DE60137037D1 DE60137037T DE60137037T DE60137037D1 DE 60137037 D1 DE60137037 D1 DE 60137037D1 DE 60137037 T DE60137037 T DE 60137037T DE 60137037 T DE60137037 T DE 60137037T DE 60137037 D1 DE60137037 D1 DE 60137037D1
- Authority
- DE
- Germany
- Prior art keywords
- hetero
- double bond
- rarb
- polymerization
- microtubulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 2
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 238000006116 polymerization reaction Methods 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 102000004243 Tubulin Human genes 0.000 abstract 3
- 108090000704 Tubulin Proteins 0.000 abstract 3
- 125000004122 cyclic group Chemical group 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical class O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 238000000134 MTT assay Methods 0.000 abstract 1
- 231100000002 MTT assay Toxicity 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- -1 piperazinedione compound Chemical class 0.000 abstract 1
- 239000012679 serum free medium Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30419100P | 2000-05-09 | 2000-05-09 | |
PCT/US2001/014721 WO2001095858A2 (en) | 2000-05-09 | 2001-05-08 | Piperazinedione compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60137037D1 true DE60137037D1 (de) | 2009-01-29 |
Family
ID=23175471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60137037T Expired - Lifetime DE60137037D1 (de) | 2000-05-09 | 2001-05-08 | Piperazindion-verbindungen |
Country Status (14)
Country | Link |
---|---|
US (1) | US6635649B2 (de) |
EP (1) | EP1282609B1 (de) |
JP (1) | JP5101781B2 (de) |
KR (1) | KR100852965B1 (de) |
CN (1) | CN100522949C (de) |
AT (1) | ATE417614T1 (de) |
BR (1) | BR0110745A (de) |
CZ (1) | CZ301743B6 (de) |
DE (1) | DE60137037D1 (de) |
HU (1) | HUP0302358A3 (de) |
NO (1) | NO326341B1 (de) |
RU (1) | RU2269520C2 (de) |
WO (1) | WO2001095858A2 (de) |
ZA (1) | ZA200209917B (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7288545B2 (en) * | 2000-05-09 | 2007-10-30 | Angiorx Corporation | Piperazinedione compounds |
WO2002011676A2 (en) | 2000-08-04 | 2002-02-14 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US7935704B2 (en) * | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
EP1571970B1 (de) * | 2002-10-02 | 2011-08-17 | DMI Biosciences, Inc. | Diagnose und überwachung von krankheiten |
WO2004103304A2 (en) * | 2003-05-15 | 2004-12-02 | Dmi Biosciences, Inc. | Treatment of t-cell mediated diseases |
AU2004275821A1 (en) * | 2003-09-25 | 2005-04-07 | Dmi Biosciences Inc. | Methods and products which utilize N-acyl-L-aspartic acid |
NZ548659A (en) * | 2004-02-04 | 2011-01-28 | Nereus Pharmaceuticals Inc | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US8129527B2 (en) * | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
EP2300011A4 (de) * | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | Therapeutische verfahren und verbindungen |
RU2519948C2 (ru) * | 2008-08-22 | 2014-06-20 | Бритиш Коламбиа Кэнсер Эйдженси Бранч | Низкомолекулярные ингибиторы n-концевой активации рецептора андрогенов |
EP2419424A4 (de) * | 2009-04-16 | 2014-01-08 | Telik Inc | Substituierte 4-amino-5-benzoyl-2-(phenylamino)thiophen-3-carbonitrile und substituierte 4-amino-5-benzoyl-2-(phenylamino)thiophen-3-carboxamide als tubulinpolymerisierungshemmer |
JP2013537195A (ja) | 2010-09-07 | 2013-09-30 | ディエムアイ アクイジション コーポレイション | 疾患の治療 |
US8710062B2 (en) * | 2011-03-11 | 2014-04-29 | Taipei Medical University | Piperazinedione compounds |
KR102032400B1 (ko) | 2011-10-10 | 2019-10-15 | 앰피오 파마슈티컬스 인코퍼레이티드 | 퇴행성 관절 질환의 치료 |
CN103841934A (zh) | 2011-10-10 | 2014-06-04 | 安皮奥制药股份有限公司 | 增强免疫耐受的可植入的医疗装置及其制造与植入方法 |
EP2771007B1 (de) | 2011-10-28 | 2018-04-04 | Ampio Pharmaceuticals, Inc. | Behandlung von rhinitis |
WO2014145729A2 (en) | 2013-03-15 | 2014-09-18 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
JP6311097B2 (ja) * | 2013-07-31 | 2018-04-18 | 学校法人東京薬科大学 | 微小管脱重合剤 |
EP4066836A1 (de) | 2014-08-18 | 2022-10-05 | Ampio Pharmaceuticals, Inc. | Behandlung von gelenkerkrankungen |
CN104356077B (zh) * | 2014-09-11 | 2016-09-14 | 中国科学院南海海洋研究所 | 一类不对称酰基保护的2,5-二酮哌嗪衍生物及其制备方法和应用 |
AU2016229294B2 (en) | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
BR112017018964A2 (pt) | 2015-03-06 | 2018-05-22 | Beyondspring Pharmaceuticals Inc | uso de plinabulin e métodos para tratar tumor cerebral |
WO2016209969A1 (en) | 2015-06-22 | 2016-12-29 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
DK3334726T3 (da) | 2015-07-13 | 2022-05-16 | Beyondspring Pharmaceuticals Inc | Plinabulinsammensætninger |
CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
EP3463337A4 (de) | 2016-06-06 | 2020-02-12 | Beyondspring Pharmaceuticals, Inc. | Zusammensetzung und verfahren zur reduzierung von neutropenie |
WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
US11786523B2 (en) | 2018-01-24 | 2023-10-17 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia |
CN109580801B (zh) * | 2018-06-26 | 2021-09-07 | 深圳海王医药科技研究院有限公司 | 一种检测微管蛋白抑制剂及相关杂质的高效液相色谱法 |
CN112010930B (zh) * | 2019-05-28 | 2022-08-02 | 首都医科大学 | Rgd修饰的五环哌嗪二酮及其制备和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5973574A (ja) * | 1982-10-21 | 1984-04-25 | Grelan Pharmaceut Co Ltd | 環状ジペプチド類 |
GB8609908D0 (en) * | 1986-04-23 | 1986-05-29 | Fujisawa Pharmaceutical Co | Piperazine compound |
US4806538A (en) * | 1984-11-02 | 1989-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine compound as PAF-antagonist |
DK181687A (da) * | 1986-04-23 | 1987-10-24 | Fujisawa Pharmaceutical Co | Piperazinderivater og fremgangsmaade til fremstiling deraf |
GB9217331D0 (en) * | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
IL112627A0 (en) * | 1994-02-14 | 1995-05-26 | Xenova Ltd | Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them |
GB9402807D0 (en) * | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
JP3795093B2 (ja) * | 1994-11-25 | 2006-07-12 | キッセイ薬品工業株式会社 | 1−ヒドロキシインドール誘導体 |
JP3131574B2 (ja) * | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤 |
-
2001
- 2001-05-08 HU HU0302358A patent/HUP0302358A3/hu unknown
- 2001-05-08 JP JP2002510040A patent/JP5101781B2/ja not_active Expired - Fee Related
- 2001-05-08 BR BR0110745-3A patent/BR0110745A/pt not_active Application Discontinuation
- 2001-05-08 DE DE60137037T patent/DE60137037D1/de not_active Expired - Lifetime
- 2001-05-08 EP EP01975152A patent/EP1282609B1/de not_active Expired - Lifetime
- 2001-05-08 CZ CZ20023693A patent/CZ301743B6/cs not_active IP Right Cessation
- 2001-05-08 US US09/851,077 patent/US6635649B2/en not_active Expired - Fee Related
- 2001-05-08 RU RU2002132897/04A patent/RU2269520C2/ru not_active IP Right Cessation
- 2001-05-08 WO PCT/US2001/014721 patent/WO2001095858A2/en active IP Right Grant
- 2001-05-08 CN CNB018125212A patent/CN100522949C/zh not_active Expired - Fee Related
- 2001-05-08 KR KR1020027015025A patent/KR100852965B1/ko not_active IP Right Cessation
- 2001-05-08 AT AT01975152T patent/ATE417614T1/de not_active IP Right Cessation
-
2002
- 2002-11-08 NO NO20025373A patent/NO326341B1/no not_active IP Right Cessation
- 2002-12-06 ZA ZA200209917A patent/ZA200209917B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200209917B (en) | 2004-04-28 |
JP2004510701A (ja) | 2004-04-08 |
JP5101781B2 (ja) | 2012-12-19 |
EP1282609A2 (de) | 2003-02-12 |
RU2269520C2 (ru) | 2006-02-10 |
CN1441789A (zh) | 2003-09-10 |
CN100522949C (zh) | 2009-08-05 |
EP1282609A4 (de) | 2003-06-04 |
US20020028819A1 (en) | 2002-03-07 |
BR0110745A (pt) | 2003-12-30 |
KR20030005336A (ko) | 2003-01-17 |
HUP0302358A2 (hu) | 2003-11-28 |
CZ20023693A3 (cs) | 2003-05-14 |
EP1282609B1 (de) | 2008-12-17 |
US6635649B2 (en) | 2003-10-21 |
WO2001095858A3 (en) | 2002-03-21 |
NO20025373L (no) | 2002-12-13 |
CZ301743B6 (cs) | 2010-06-09 |
NO20025373D0 (no) | 2002-11-08 |
HUP0302358A3 (en) | 2007-09-28 |
WO2001095858A2 (en) | 2001-12-20 |
NO326341B1 (no) | 2008-11-10 |
ATE417614T1 (de) | 2009-01-15 |
KR100852965B1 (ko) | 2008-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60137037D1 (de) | Piperazindion-verbindungen | |
TW200730514A (en) | Morpholine type cinnamide compound | |
NO20066015L (no) | Fuserte heterosykliske forbindelser | |
ATE491704T1 (de) | 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten | |
ECSP10010006A (es) | Derivado de oxopirazina y herbicida | |
EA200700997A1 (ru) | 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ | |
ATE427932T1 (de) | 11beta-hsd1-inhibitoren | |
UA84878C2 (ru) | Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения | |
DK1569899T3 (da) | Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1) | |
CY1109441T1 (el) | Ενδιαμεσα προϊοντα για την παραγωγη διοξανιου-2-αλκυλκαρβαμικου | |
DK1763534T3 (da) | Nye 2-substituerede D-homo-estra-1,3,5(10)-triener som inhibitorer af 17beta-hydroxysteroiddehydrogenasen type 1 | |
BG105666A (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex | |
CO5690604A2 (es) | Derivados de [6,7-dihidro-5h-imidazo[1.2-alfa]imidazol-3- sulfonilamino]-propionamida | |
ATE325607T1 (de) | Aptoptoseinhibitoren | |
CY1110284T1 (el) | Παραγωγα της 2-αμινο-4-πυριδυλομεθυλο-θειαζολινης και η χρηση τους ως αναστολεις της επαγωγιμης συνθασης νο | |
MXPA02012054A (es) | Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v. | |
ES465034A1 (es) | Procedimiento para la preparacion de derivados de acidos n- (benzotiazol-2-il)-oxamidicos. | |
TR200102514T2 (tr) | COPD tedavisi için metod | |
DE602005024623D1 (de) | Neue betulinsäurederivate kondensiert im a-ring mit einer heterozyklischen gruppe | |
NO953118D0 (no) | Morfolinderivat | |
DK1637141T3 (da) | Stabiliseret proteasesammensætning omfattende en serinprotease, morpholinderivater og reversible inhibitorer af serinproteasen | |
DE60105618D1 (de) | Dihydroporphyrinderivate und ihre verwendung | |
ATE380810T1 (de) | Protein-tyrosine-kinase-inhibitoren | |
WO2003106440A3 (en) | PROCESS FOR THE SYNTHESIS OF A BENZAMIDE DERIVATIVE | |
NZ336362A (en) | Use of a 15-keto-prostaglandin compound as a portal hypertension inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |